Inhibrx Biosciences (INBX) Payables: 2023-2025
Historic Payables for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to $6.8 million.
- Inhibrx Biosciences' Payables fell 45.25% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year change of. This contributed to the annual value of $9.2 million for FY2024, which is 15.60% down from last year.
- As of Q3 2025, Inhibrx Biosciences' Payables stood at $6.8 million, which was down 18.32% from $8.3 million recorded in Q2 2025.
- In the past 5 years, Inhibrx Biosciences' Payables ranged from a high of $13.0 million in Q2 2024 and a low of $6.8 million during Q3 2025.
- For the 3-year period, Inhibrx Biosciences' Payables averaged around $9.9 million, with its median value being $9.2 million (2024).
- Data for Inhibrx Biosciences' Payables shows a maximum YoY slumped of 45.25% (in 2025) over the last 5 years.
- Inhibrx Biosciences' Payables (Quarterly) stood at $11.0 million in 2023, then decreased by 15.60% to $9.2 million in 2024, then slumped by 45.25% to $6.8 million in 2025.
- Its Payables was $6.8 million in Q3 2025, compared to $8.3 million in Q2 2025 and $8.9 million in Q1 2025.